333 related articles for article (PubMed ID: 20714115)
1. Growth patterns in the first three years of life in children with classical congenital adrenal hyperplasia diagnosed by newborn screening and treated with low doses of hydrocortisone.
Bonfig W; Schmidt H; Schwarz HP
Horm Res Paediatr; 2011; 75(1):32-7. PubMed ID: 20714115
[TBL] [Abstract][Full Text] [Related]
2. Growth pattern of untreated boys with simple virilizing congenital adrenal hyperplasia indicates relative androgen insensitivity during the first six months of life.
Bonfig W; Schwarz HP
Horm Res Paediatr; 2011; 75(4):264-8. PubMed ID: 21196707
[TBL] [Abstract][Full Text] [Related]
3. Experience with long-term glucocorticoid treatment in congenital adrenal hyperplasia: growth pattern compared with genetic height potential.
Aycan Z; Ocal G; Berberoglu M; Cetinkaya E; Adiyaman P; Evliyaoglu O
J Pediatr Endocrinol Metab; 2006 Mar; 19(3):245-51. PubMed ID: 16607925
[TBL] [Abstract][Full Text] [Related]
4. Treatment and disease effects on short-term growth and adult height in children and adolescents with 21-hydroxylase deficiency.
Hauffa BP; Winter A; Stolecke H
Klin Padiatr; 1997; 209(2):71-7. PubMed ID: 9113619
[TBL] [Abstract][Full Text] [Related]
5. The relation of peripubertal and pubertal growth to final adult height in children with classic congenital adrenal hyperplasia.
Bomberg EM; Addo OY; Kyllo J; Gonzalez-Bolanos MT; Ltief AM; Pittock S; Himes JH; Miller BS; Sarafoglou K
J Pediatr; 2015 Mar; 166(3):743-50. PubMed ID: 25557963
[TBL] [Abstract][Full Text] [Related]
6. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Völkl TM; Simm D; Beier C; Dörr HG
Pediatrics; 2006 Jan; 117(1):e98-105. PubMed ID: 16396852
[TBL] [Abstract][Full Text] [Related]
7. Long-term Growth in Congenital Adrenal Hyperplasia.
Maheshwari A; Khadilkar V; Gangodkar P; Khadilkar A
Indian J Pediatr; 2019 Feb; 86(2):154-158. PubMed ID: 30097840
[TBL] [Abstract][Full Text] [Related]
8. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty.
Bonfig W; Bechtold S; Schmidt H; Knorr D; Schwarz HP
J Clin Endocrinol Metab; 2007 May; 92(5):1635-9. PubMed ID: 17299071
[TBL] [Abstract][Full Text] [Related]
9. Growth of patients with congenital adrenal hyperplasia due to 21-hydroxylase in infancy, glucocorticoid requirement and the role of mineralocorticoid therapy.
Sellick J; Aldridge S; Thomas M; Cheetham T
J Pediatr Endocrinol Metab; 2018 Sep; 31(9):1019-1022. PubMed ID: 30173205
[TBL] [Abstract][Full Text] [Related]
10. [Growth and adult height in patients with congenital adrenal hyperplasia].
Kolousková S; Zemková D; Snajderová M; Lebl J
Cas Lek Cesk; 1995 Nov; 134(21):689-91. PubMed ID: 8556761
[TBL] [Abstract][Full Text] [Related]
11. HYDROCORTISONE THERAPY AND GROWTH TRAJECTORY IN CHILDREN WITH CLASSICAL CONGENITAL ADRENAL HYPERPLASIA.
Bizzarri C; Improda N; Maggioli C; Capalbo D; Roma S; Porzio O; Salerno M; Cappa M
Endocr Pract; 2017 May; 23(5):546-556. PubMed ID: 28225306
[TBL] [Abstract][Full Text] [Related]
12. Blood pressure, fludrocortisone dose and plasma renin activity in children with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency followed from birth to 4 years of age.
Bonfig W; Schwarz HP
Clin Endocrinol (Oxf); 2014 Dec; 81(6):871-5. PubMed ID: 24818525
[TBL] [Abstract][Full Text] [Related]
13. Molecular testing in congenital adrenal hyperplasia due to 21α-hydroxylase deficiency in the era of newborn screening.
Sarafoglou K; Lorentz CP; Otten N; Oetting WS; Grebe SK
Clin Genet; 2012 Jul; 82(1):64-70. PubMed ID: 21534945
[TBL] [Abstract][Full Text] [Related]
14. Growth of patients with 21-hydroxylase deficiency: an analysis of the factors influencing adult height.
Jääskeläinen J; Voutilainen R
Pediatr Res; 1997 Jan; 41(1):30-3. PubMed ID: 8979286
[TBL] [Abstract][Full Text] [Related]
15. Monitoring treatment in congenital adrenal hyperplasia.
Appan S; Hindmarsh PC; Brook CG
Arch Dis Child; 1989 Sep; 64(9):1235-9. PubMed ID: 2640553
[TBL] [Abstract][Full Text] [Related]
16. Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism.
Cordeiro GV; Silva IN; Goulart EM; Chagas AJ; Kater CE
Arq Bras Endocrinol Metabol; 2013 Mar; 57(2):126-31. PubMed ID: 23525290
[TBL] [Abstract][Full Text] [Related]
17. Sodium Chloride Supplementation Is Not Routinely Performed in the Majority of German and Austrian Infants with Classic Salt-Wasting Congenital Adrenal Hyperplasia and Has No Effect on Linear Growth and Hydrocortisone or Fludrocortisone Dose.
Bonfig W; Roehl F; Riedl S; Brämswig J; Richter-Unruh A; Fricke-Otto S; Hübner A; Bettendorf M; Schönau E; Dörr H; Holl RW; Mohnike K
Horm Res Paediatr; 2018; 89(1):7-12. PubMed ID: 29073619
[TBL] [Abstract][Full Text] [Related]
18. Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation.
Bonfig W; Pozza SB; Schmidt H; Pagel P; Knorr D; Schwarz HP
J Clin Endocrinol Metab; 2009 Oct; 94(10):3882-8. PubMed ID: 19622620
[TBL] [Abstract][Full Text] [Related]
19. Effect of the dose of oral hydrocortisone on growth rate during long-term treatment of children with salt losing congenital adrenal hyperplasia.
Ciaccio M; Montiveros C; Rivarola MA; Belgorosky A
Medicina (B Aires); 2002; 62(6):551-4. PubMed ID: 12532689
[TBL] [Abstract][Full Text] [Related]
20. Growth pattern during the first 36 months of life in congenital adrenal hyperplasia (21-hydroxylase deficiency).
Gasparini N; Di Maio S; Salerno M; Argenziano A; Franzese A; Tenore A
Horm Res; 1997; 47(1):17-22. PubMed ID: 9010713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
